Sector: Health Care
Director information for VERTEX PHARMACEUTICALS INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alan Garber | President, Harvard University; Director | 70 | ["President of Harvard University since August 2024", "Provost of Harvard University and the Mallinckrodt Professor of Health Care Policy at Harvard Medical School", "Professor of Economics in the Faculty of Arts and Sciences", "Professor of Public Policy in the Harvard Kennedy School of Government", "Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health", "Henry J. Kaiser Jr. Professor at Stanford University from 1998 until 2011", "Member of the National Academy of Medicine", "Member of the board of Directors of Exelixis, Inc.", "Current Research Associate with the National Bureau of Economic Research", "Served for nineteen years as founding Director of its Health Care Program", "Extensive leadership experience in healthcare economics"] | ["Corporate Governance and Nominating Committee", "Science and Technology Committee"] | 2026 |
| Bruce Sachs | Partner Emeritus, Charles River Ventures; Lead Independent Director | 66 | ["Partner Emeritus at Charles River Ventures", "General Partner at CRV for more than 20 years", "Executive Vice President and General Manager of Ascend Communications, Inc.", "President and Chief Executive Officer of Stratus Computer, Inc.", "Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc.", "President and Chief Executive Officer of Xylogics, Inc.", "Holds a B.S.E.E. in electrical engineering from Bucknell University", "Holds an M.E.E. in electrical engineering from Cornell University", "Holds an M.B.A. from Northeastern University"] | ["Management Development and Compensation Committee", "Corporate Governance and Nominating Committee"] | 2026 |
| Charles F. Wagner, Jr. | Executive Vice President, Chief Operating and Financial Officer | [] | [] | 2026 | |
| Diana McKenzie | Former Chief Information Officer, WorkdayFormer Chief Information Officer, Amgen; Director | 61 | ["Chief Information Officer of Workday, Inc., from 2016 until April 2019", "Held roles of increasing responsibility at Amgen Inc. for 12 years, most recently serving as Senior Vice President and Chief Information Officer", "Held various leadership roles at Eli Lilly and Company for 17 years", "Member of the board of directors of Change Healthcare, Inc. from August 2019 until it was acquired in October 2022", "Bachelor of Science degree in Computer Information Systems from Purdue University", "Completed the Information Technology Management Program at UCLA", "CERT Certification for Cybersecurity Oversight from Carnegie Mellon\u2019s Software Engineering Institute"] | ["Audit and Finance Committee", "Management Development and Compensation Committee"] | 2026 |
| Jeffrey Leiden | Executive Chairman, Vertex | 70 | ["Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated from 2012 through March 2020", "Chairman of Board of Directors of Vertex Pharmaceuticals Incorporated since 2012; previously served as lead independent director from 2010 through 2011", "Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 to 2012", "President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group and a member of the board of directors of Abbott Laboratories from 2001 to 2006", "Held several academic appointments from 1987 to 2000, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago", "Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health", "Professor of Medicine at Harvard Medical School", "Elected member of the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences", "Member of the board of directors of Quest Diagnostics Incorporated from 2014 to May 2019", "Member of the board of directors and non-executive Vice Chairman of Shire plc from 2006 to 2012", "Chairman of Revolution Healthcare Acquisition Corp. from April 2021 to December 2022", "Holds M.D., Ph.D. and B.A. degrees from the University of Chicago"] | [] | 2026 |
| Jennifer Schneider | Co-Founder and CEO, Homeward Health Inc.; Co-Founder and Chief Executive Officer | 51 | ["Co-Founder and Chief Executive Officer of Homeward Health Inc. since 2022", "President of Livongo Health from December 2018 to October 2020", "Chief Medical Officer of Livongo Health from September 2015 to December 2018", "Served in multiple leadership roles at Castlight Health, Inc. from 2010 to 2015", "Member of the board of directors at Revolution Healthcare Acquisition Corp. from March 2021 to December 2022", "Member of the board of directors at Health Assurance Acquisition Corp. until November 2022", "Holds a B.S. in Biology, an M.D. from Johns Hopkins, and an M.S. in Health Services Research from Stanford"] | ["Management Development and Compensation Committee"] | 2026 |
| Lloyd Carney | Chief Executive Officer, Carney Global Ventures, LLCFormer CEO, Brocade Communications; Director | 64 | ["Chief Executive Officer and Chairman of Carney Global Ventures, LLC since March 2007", "Chief Acquisition Officer of Carney Technology Acquisition Corp. II from October 2020 until February 2023", "Chief Executive Officer of ChaSerg Technology Acquisition Corp. from September 2018 until March 2020", "Chief Executive Officer and Director of Brocade Communications Systems Inc. from 2013 until it was acquired by Broadcom in 2017", "Chief Executive Officer of Xsigo Systems from 2008 until it was acquired by Oracle in 2012", "Chief Executive Officer and Chairman of Micromuse Inc. from 2003 until it was acquired by IBM in 2006", "Member of the board of directors of Nuance Communications Inc. until it was acquired by Microsoft Corp in March 2022", "Ambassador/Special Investment Envoy for Technology Jamaica since May 2023", "Chancellor for the University of Technology, Jamaica since August 2022", "Bachelor of Science degree in Electrical Engineering Technology from Wentworth Institute of Technology", "Master of Science degree in Applied Business Management from Lesley College", "Honorary Doctorate degree in Engineering from Wentworth Institute of Technology", "Honorary Doctorate degree in Technology from University of Technology Jamaica", "Strong business judgment from senior executive and board member experience in global technology companies", "Extensive experience in operations, strategic planning, finance, information technology, cybersecurity, and risk management"] | ["Corporate Governance and Nominating Committee", "Audit and Finance Committee"] | 2026 |
| Michel Lagarde | Former Executive Vice President and Chief Operating Officer, Thermo Fisher Scientific Inc.; Director | 52 | ["Former Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific Inc.", "Executive Vice President at Thermo Fisher from 2019 through 2021", "Senior Vice President and President, Pharma Services at Thermo Fisher from 2017 to 2019", "President and Chief Operating Officer of Patheon N.V. from 2016 to 2017", "Managing Director of JLL Partners from 2008 to 2016", "Holds a bachelor\u2019s degree in business administration from European University in Antwerp", "Executive master\u2019s degree in finance and control from the University of Maastricht and University of Amsterdam"] | ["Audit and Finance Committee"] | 2026 |
| Nancy Thornberry | Former CEO, Kallyope, Inc.; Director | 69 | ["Founder and Chief Executive Officer of Kallyope, Inc.", "Self-employed consultant to biotechnology and pharmaceutical companies", "Roles at Merck & Co., Inc. for more than 30 years, most recently as Senior Vice President and Franchise Head, Diabetes and Endocrinology", "Holds a B.S. in Chemistry and Biology from Muhlenberg College", "Over 30 years of experience in pharmaceutical and biotechnology industries", "Leadership experience in critical scientific roles driving innovation"] | ["Science and Technology Committee"] | 2026 |
| Reshma Kewalramani | CEO and President, Vertex; Chief Executive Officer and President | 53 | ["Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated since April 2020", "Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Incorporated from 2018 through March 2020", "Senior Vice President, Late Development of Vertex from 2017 until 2018", "Served in roles of increasing responsibility at Amgen Inc. from 2004 to 2017, most recently as Vice President and Head of U.S. Medical Organization", "Industry representative to the FDA\u2019s Endocrine and Metabolic Drug Advisory Committee from 2014 through 2019", "Member of the Board of Directors of Ginkgo Bioworks Holdings, Inc., from 2021 to 2024", "Holds a B.A. from Boston University and an M.D. from Boston University School of Medicine", "Completed her internship and residency in Internal Medicine at the Massachusetts General Hospital", "Fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women\u2019s Hospital combined program", "Alumna of the Harvard Business School, having completed the General Management Program"] | [] | 2026 |
| Sangeeta Bhatia | John J. and Dorothy Wilson Professor of Health Sciences & Technology/Electrical Engineering & Computer Science, MIT; Chair – Science and Technology Committee | 57 | ["John J. and Dorothy Wilson Professor of Health Sciences & Technology/Electrical Engineering & Computer Science at MIT since 2005", "Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research at MIT since 2016", "Investigator of the Howard Hughes Medical Institute at MIT since 2008", "Co-Founder of Ropirio Therapeutics since 2023", "Co-Founder of Amplifyer Bio since 2023", "Co-Founder of Matrisome Bio since 2023", "Co-Founder of Port Therapeutics since 2022", "Co-Founder of Satellite Bio since 2020", "Co-Founder of Glympse Bio from 2018 until it was acquired in August 2023", "Professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005", "Member of the Department of Medicine at Brigham and Women\u2019s Hospital", "Member of the Broad Institute", "Holds a Sc.B. in biomedical engineering from Brown University", "Holds an S.M. and Ph.D. in Mechanical Engineering from MIT", "Holds an M.D. from Harvard Medical School"] | ["Science and Technology Committee", "Corporate Governance and Nominating Committee"] | 2026 |
| Suketu Upadhyay | Chief Financial Officer and Executive Vice President, Zimmer Biomet; Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain | 57 | ["Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain of Zimmer Biomet since July 2019", "Senior Vice President, Global Financial Operations at Bristol-Myers Squibb from 2016 to June 2019", "Executive Vice President and Chief Financial Officer of Endo International from 2013 to 2016", "Interim Chief Financial Officer and Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of Becton Dickinson", "Senior Vice President of Global Financial Planning and Analysis and Vice President and Chief Financial Officer of Becton Dickinson\u2019s international business", "Held a number of global finance and strategy roles across AstraZeneca and Johnson & Johnson", "Spent the early part of his career in public accounting with KPMG", "Holds a Bachelor of Science in Finance from Albright College and an MBA from The Fuqua School of Business at Duke University"] | ["Audit and Finance Committee", "Management Development and Compensation Committee"] | 2026 |
